Zhu S - Search Results

1

Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.

Tan W, Zhu S, Cao J, Zhang L, Li W, Liu K, Zhong J, Shang C, Chen Y. Tan W, et al. Among authors: zhu s. Oncol Res. 2017 Nov 2;25(9):1543-1553. doi: 10.3727/096504017X14886444100783. Epub 2017 Mar 8. Oncol Res. 2017. PMID: 28276313 Free PMC article.

2

Low expression of VSIG4 is associated with poor prognosis in hepatocellular carcinoma patients with hepatitis B infection.

Zhu S, Tan W, Li W, Zhou R, Wu X, Chen X, Li W, Shang C, Chen Y. Zhu S, et al. Cancer Manag Res. 2018 Sep 20;10:3697-3705. doi: 10.2147/CMAR.S165822. eCollection 2018. Cancer Manag Res. 2018. PMID: 30288101 Free PMC article.

3

TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.

Tan W, Luo X, Li W, Zhong J, Cao J, Zhu S, Chen X, Zhou R, Shang C, Chen Y. Tan W, et al. Among authors: zhu s. EBioMedicine. 2019 Feb;40:446-456. doi: 10.1016/j.ebiom.2018.12.047. Epub 2018 Dec 26. EBioMedicine. 2019. PMID: 30594557 Free PMC article.

4

Is lymph node dissection necessary for resectable intrahepatic cholangiocarcinoma? A systematic review and meta-analysis.

Zhou R, Lu D, Li W, Tan W, Zhu S, Chen X, Min J, Shang C, Chen Y. Zhou R, et al. Among authors: zhu s. HPB (Oxford). 2019 Jul;21(7):784-792. doi: 10.1016/j.hpb.2018.12.011. Epub 2019 Mar 14. HPB (Oxford). 2019. PMID: 30878490 Free article.

5

miR-1226-3p Promotes Sorafenib Sensitivity of Hepatocellular Carcinoma via Downregulation of DUSP4 Expression.

Chen X, Tan W, Li W, Li W, Zhu S, Zhong J, Shang C, Chen Y. Chen X, et al. Among authors: zhu s. J Cancer. 2019 Jun 2;10(12):2745-2753. doi: 10.7150/jca.31804. eCollection 2019. J Cancer. 2019. PMID: 31258782 Free PMC article.

6

Low expression of long noncoding RNA CTC-297N7.9 predicts poor prognosis in patients with hepatocellular carcinoma.

Zhu S, Huang X, Zhang K, Tan W, Lin Z, He Q, Chen Y, Shang C. Zhu S, et al. Cancer Med. 2019 Dec;8(18):7679-7692. doi: 10.1002/cam4.2618. Epub 2019 Nov 1. Cancer Med. 2019. PMID: 31674731 Free PMC article.

7

miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1.

Tan W, Lin Z, Chen X, Li W, Zhu S, Wei Y, Huo L, Chen Y, Shang C. Tan W, et al. Among authors: zhu s. Ann Transl Med. 2021 Jan;9(1):38. doi: 10.21037/atm-20-2081. Ann Transl Med. 2021. PMID: 33553331 Free PMC article.

8

High Expression of Long Non-Coding RNA TMCO1-AS1 is Associated With Poor Prognosis of Hepatocellular Carcinoma.

Huang X, Zhu S, Zhang K, Tan W, Chen Y, Shang C. Huang X, et al. Among authors: zhu s. Front Mol Biosci. 2022 Jan 24;9:814058. doi: 10.3389/fmolb.2022.814058. eCollection 2022. Front Mol Biosci. 2022. PMID: 35141283 Free PMC article.

9

Corrigendum to "TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma" [EBioMedicine 40 (2019) 446-456].

Tan W, Luo X, Li W, Zhong J, Cao J, Zhu S, Chen X, Zhou R, Shang C, Chen Y. Tan W, et al. Among authors: zhu s. EBioMedicine. 2022 Jun;80:104074. doi: 10.1016/j.ebiom.2022.104074. Epub 2022 May 20. EBioMedicine. 2022. PMID: 35605430 Free PMC article. No abstract available.

10

GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma.

Tan W, Zhang K, Chen X, Yang L, Zhu S, Wei Y, Xie Z, Chen Y, Shang C. Tan W, et al. Among authors: zhu s. J Adv Res. 2023 Feb;44:173-183. doi: 10.1016/j.jare.2022.03.012. Epub 2022 Mar 21. J Adv Res. 2023. PMID: 36725188 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17,767 results

Search Page

Filters